title: Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
abstract: The purpose of this study was to evaluate the efficacy and toxicity of a single-agent, dose-intensified doxorubicin protocol in canine hemangiosarcoma (HSA). Canine HSA is a highly malignant tumor, and most affected dogs die within 6 months of diagnosis. Doxorubicin is the most, and possibly the only, effective chemotherapeutic drug for this malignancy, but it provides only moderate improvement in survival. On the basis of previous studies reporting similar survival in dogs treated with doxorubicin as a single agent and doxorubicin-based combination chemotherapy and the concept of summation dose intensity, a dose-intensified single-agent doxorubicin protocol was initiated. Twenty dogs with HSA were recruited to participate in this study. Workup and staging were performed according to standard practice. Chemotherapy was initiated within 3 weeks of surgery. Doxorubicin was scheduled to be administered at 30 mg/m2 i.v. every 2 weeks for a total of 5 treatments. The dogs were monitored for toxicity and signs of recurrence during and at regular intervals after chemotherapy. The protocol was tolerated well. No dogs were hospitalized because of adverse effects or developed clinical signs consistent with doxorubicin-induced cardiomyopathy. There was a significant difference in survival in dogs with stage I and I1 HSA compared with dogs with stage III HSA. with median survival times of 257, 210, and 107 days, respectively. These results are slightly better than the historical control with respect to toxicity and efficacy but are not statistically different from what is achieved with standard treatments. There was no association between dose intensity and outcome.
authors.affiliation: Department of Clinical Studies, Matthew J. Ryan Veterinary Hospital of The University of Pennsylvania, 3900 Delancey Street, Philadelphia, PA 19104, USA. karins@vet.upenn.edu
authors.forename: Karin U
authors.initials: KU
authors.lastname: Sorenmo
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Baez
authors.forename: Craig A
authors.initials: CA
authors.lastname: Clifford
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Mauldin
authors.forename: Beth
authors.initials: B
authors.lastname: Overley
authors.forename: Katherine
authors.initials: K
authors.lastname: Skorupski
authors.forename: Roxanne
authors.initials: R
authors.lastname: Bachman
authors.forename: Marissa
authors.initials: M
authors.lastname: Samluk
authors.forename: Frances
authors.initials: F
authors.lastname: Shofer
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000662:veterinary*; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin